This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.




T

Specific gabapentin binding (cpm)

FIG.

+

FIG. 4A




p <0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

FIC. 4R





p <0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

R217A HETEROZYGOTE Mice (N = 7-8)

Early Phase (0-10 min)


150

100

Time spent licking (seconds)

20

R217A HETEROZYGOTE Mice (N = 7-8)



p <0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)


p <0.05 (t-test: relative to vehicle-treated controls) Treatment (100 mg/kg PO @ - 120 min)

Pregabalin

Vehicle

IG. 4E


R217A HOMOZYGOTE Mice (N = 7)




no significant differences between Vehicle and PGB-treated groups

Treatment (100 mg/kg PO @ - 120 min)


FIG. 4F





no significant differences between Vehicle and PGB-treated groups


Treatment (100 mg/kg PO @ - 120 min)



* p <0.05 (t-test: relative to wild type controls)

M

R217A





α 28 -

+

FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B

